From mRNA metabolism to cancer therapy: Chronic myelogenous leukemia shows the way

Clinical Cancer Research

Volumn 13, Issue 6, 2007, Pages 1638-1642

  Perrotti, Danilo ^a,b   Neviani, Paolo ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; FUS PROTEIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN A1; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN E2; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN K; IMATINIB; LA ANTIGEN; MESSENGER RNA; NILOTINIB; RNA BINDING PROTEIN; SINGLE STRANDED DNA BINDING PROTEIN; UNCLASSIFIED DRUG; AUTOANTIGEN; CCAAT ENHANCER BINDING PROTEIN; CUGBP1 PROTEIN, HUMAN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; HNRPK PROTEIN, HUMAN; LA PROTEIN, HUMAN (349 364); LA PROTEIN, HUMAN (349-364); MDM2 PROTEIN, HUMAN; NONHISTONE PROTEIN; PEPTIDE FRAGMENT; PHOSPHOPROTEIN PHOSPHATASE; PROTEIN MDM2; RIBONUCLEOPROTEIN; SET PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ARTICLE; BLAST CELL CRISIS; CANCER THERAPY; CARCINOGENESIS; CHRONIC MYELOID LEUKEMIA; COMPREHENSION; DISEASE COURSE; HEMATOPOIETIC STEM CELL; HUMAN; MOLECULAR MECHANICS; MONOTHERAPY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA METABOLISM; TRANSLATION REGULATION; ANIMAL; BIOLOGICAL MODEL; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOANTIGENS; CCAAT-ENHANCER-BINDING PROTEINS; CHROMOSOMAL PROTEINS, NON-HISTONE; HETEROGENEOUS-NUCLEAR RIBONUCLEOPROTEINS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MODELS, BIOLOGICAL; NEOPLASMS; PEPTIDE FRAGMENTS; PHOSPHOPROTEIN PHOSPHATASE; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; RIBONUCLEOPROTEINS; RNA, MESSENGER; RNA-BINDING PROTEINS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 34250178439     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2320     Document Type: Article

References (42)

1. Kantarjian HM, Keating MJ, Talpaz M, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 1987;83:445-54.
2. Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004;103:4010-22.
3. Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999;340:1330-40.
4. Gaiger A, Henn T, Horth E, et al. Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression. Blood 1995;86:2371-8.
5. + cells from CML patients to predict the response to imatinib mesylate treatment. Blood 2005;105:4893-4.
6. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351:657-67.
7. Dierov JK, Schoppy DW, Carroll M. CML Progenitor cells have chromosomal instability and display increased DNA damage at DNA fragile sites. Blood (Suppl) 2005;106:1989.
8. Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002;21:8591-604.
9. Guerzoni C, Bardini M, Mariani SA, et al. Inducible activation of CEBPB, a gene negatively regulated by BCR/ABL, inhibits proliferation and promotes differentiation of BCR/ABL-expressing cells. Blood 2006;107:4080-9.
10. Iervolino A, Santilli G, Trotta R, et al. hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis. Mol Cell Biol 2002;22:2255-66.
11. Notari M, Neviani P, Santhanam R, et al. A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 2006;107:2507-16.
12. Perrotti D, Bonatti S, Trotta R, et al. TLS/FUS, a pro-oncogene involved in multiple chromosomal translocations, is a novel regulator of BCR/ABL-mediated leukemogenesis. EMBO J 1998;17:4442-55.
13. Perrotti D, Cesi V, Trotta R, et al. BCR-ABL suppresses C/EBPα expression through inhibitory action of hnRNP E2. Nat Genet 2002;30:48-58.
14. Trotta R, Vignudelli T, Candini O, et al. BCR/ABL activates mdm2 mRNA translation via the La antigen. Cancer Cell 2003;3:145-60.
15. Ly C, Arechiga AF, Melo JV, Walsh CM, Ong ST. Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin. Cancer Res 2003;63:5716-22.
16. Perrotti D, Turturro F, Neviani P. BCR/ABL, mRNA translation and apoptosis. Cell Death Differ 2005;12:534-40.
17. Dreyfuss G, Kim VN, Kataoka N. Messenger-RNA-binding proteins and the messages they carry. Nat Rev Mol Cell Biol 2002;3:195-205.
18. Keene JD. Ribonucleoprotein infrastructure regulating the flow of genetic information between the genome and the proteome. Proc Natl Acad Sci U S A 2001;98:7018-24.
19. Keene JD, Tenenbaum SA. Eukaryotic mRNPs may represent posttranscriptional operons. Mol Cell 2002;9:1161-7.
20. Perrotti D, Calabretta B. Post-transcriptional mechanisms in BCR/ABL leukemogenesis: role of shuttling RNA-binding proteins. Oncogene 2002;21:8577-83.
21. Perrotti D, Iervolino A, Cesi V, et al. BCR-ABL prevents c-jun-mediated and proteasome-dependent FUS (TLS) proteolysis through a protein kinase CβII-dependent pathway. Mol Cell Biol 2000;20:6159-69.
22. Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell 1992;70:901-10.
23. Evans JR, Mitchell SA, Spriggs KA, et al. Members of the poly (rC) binding protein family stimulate the activity of the c-myc internal ribosome entry segment in vitro and in vivo. Oncogene 2003;22:8012-20.
24. Michelotti EF, Michelotti GA, Aronsohn AI, Levens D. Heterogeneous nuclear ribonucleoprotein K is a transcription factor. Mol Cell Biol 1996;16:2350-60.
25. Gopal V, Kadam P, Preisler H, et al. Abnormal regulation of the myc gene in myeloid leukemia. Med Oncol Tumor Pharmacother 1992;9:139-47.
26. Wolin SL, Cedervall T. The La protein. Annu Rev Biochem 2002;71:375-403.
27. Feinstein E, Cimino G, Gale RP, et al. p53 in chronic myelogenous leukemia in acute phase. Proc Natl Acad Sci U S A 1991;88:6293-7.
28. Honda H, Ushijima T, Wakazono K, et al. Acquired loss of p53 induces blastic transformation in p210(bcr/abl)-expressing hematopoietic cells: a transgenic study for blast crisis of human CML. Blood 2000;95:1144-50.
29. Skorski T, Nieborowska-Skorska M, Wlodarski P, et al. Blastic transformation of p53-deficient bone marrow cells by p210bcr/abl tyrosine kinase. Proc Natl Acad Sci U S A 1996;93:13137-42.
30. Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of C/EBPα is required for induction of granulocytic differentiation. Blood 2003;102:1267-75.
31. Ostareck-Lederer A, Ostareck DH. Control of mRNA translation and stability in haematopoietic cells: the function of hnRNPs K and E1/E2. Biol Cell 2004;96:407-11.
32. Neviani P, Santhanam R, Trotta R, et al. The tumor suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL-regulated SET protein. Cancer Cell 2005;8:355-68.
33. Wagner K, Zhang P, Rosenbauer F, et al. Absence of the transcription factor CCAAT enhancer binding protein α results in loss of myeloid identity in bcr/abl-induced malignancy. Proc Natl Acad Sci U S A 2006;103:6338-43.
34. Perrotti D, Marcucci G, Caligiuri MA. Loss of C/EBPα and favorable prognosis of acute myeloid leukemias: a biological paradox. J Clin Oncol 2004;22:582-4.
35. Jones LC, Lin ML, Chen SS, et al. Expression of C/EBPβ from the C/ebpα gene locus is sufficient for normal hematopoiesis in vivo. Blood 2002;99:2032-6.
36. Timchenko NA, Welm AL, Lu X, Timchenko LT. CUG repeat binding protein (CUGBP1) interacts with the 5′ region of C/EBPβ mRNA and regulates translation of C/EBPβ isoforms. Nucleic Acids Res 1999;27:4517-25.
37. Dreyfuss G, Matunis MJ, Pinol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 1993;62:289-321.
38. Vera J, Jaumot M, Estanyol JM, Brun S, Agell N, Bachs O. Heterogeneous nuclear ribonucleoprotein A2 is a SET-binding protein and a PP2A inhibitor. Oncogene 2006;25:260-70.
39. Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets fromaccelerated approval to full approval. Clin Cancer Res 2005;11:12-9.
40. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51.
41. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354:2531-41.
42. Perrotti D, Neviani P. ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer 2006;95:775-81.